On July 9, Sino Biopharmaceutical rose 4.15% in regular trading, trading at 5.04 HKD/share, with turnover of approximately HKD 146 million. The stock continued to gain momentum following two landmark deals announced the previous day.

On the news front, the company disclosed on July 8 that its subsidiary Chia Tai Tianqing Pharmaceutical signed an exclusive licensing agreement with AstraZeneca for its self-developed PDE3/4 inhibitor TQC3721. Under the deal, AstraZeneca will pay a USD 200 million upfront fee, with total consideration reaching up to USD 1.9 billion including development, regulatory, and sales milestones, plus tiered royalties. AstraZeneca obtained exclusive rights to develop, manufacture, and commercialize TQC3721 outside China.

On the same day, the company also deepened its exclusive strategic partnership with GSK, securing commercialization rights for two blockbuster COPD treatments — Trelegy Ellipta and Anoro Ellipta — in mainland China. This expansion from liver disease into respiratory therapeutics marks a significant upgrade of the company's respiratory pipeline from R&D to full commercialization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)